PureTech’s Milk Exosome-Based Technology Draws R&D Pact With Roche
Executive Summary
PureTech's milk-derived exosome platform will be used by Roche to generate numerous novel antisense oligonucleotides, potentially earning PureTech more than $1bn in milestone and royalty payments.